MainBoard IPO [Initial Public Offering] is a book build issue of 61,78,800 shares [₹70.44 crore]. The issue is a combination of a fresh issue of 56,38,800 shares [₹64.28 crore] and an offer for sale of 5,40,000 shares [₹6.16 crore].
The Mahamaya Lifesciences IPO will open for subscription on November 11, 2025, and close on November 13, 2025. The Mahamaya Lifesciences IPO allotment is expected to be finalized on November 14, 2025, while the Mahamaya Lifesciences IPO to be listed on the BSE and SME on November 18, 2025.
The price band for the Mahamaya Lifesciences IPO is fixed at ₹108 to ₹114 per share. The minimum application size is 2 lots [2,400 shares], requiring a retail investor to invest at least ₹2,73,600 [based on the upper price band]. For S-HNI investors, the minimum application size is 3 lots [3,600 shares] worth ₹4,10,400, while for B-HNI investors, it is 8 lots [9,600 shares] worth ₹10,94,400.
Mahamaya Lifesciences IPO Details
| Open Date | November 11, 2025 |
| Close Date | November 13, 2025 |
| Issue Type | Book Built Issue |
| Face Value | ₹10 Equity Share |
| Price Band | ₹108 – ₹114 Per Share |
| Listing On | BSE, SME |
| Issue Size | ₹70.44 Cr. [61,78,800 Shares] |
| Fresh Issue | ₹64.28 Cr. [56,38,800 Shares] |
| Offer For Sale | ₹6.16 Cr. [5,40,000 Shares] |
| Prospectus | DRHP | RHP | Anchor Investors |
Mahamaya Lifesciences IPO Anchor Investors Details
| Anchor Bid Date | November 10, 2025 |
| Anchor Portion Size | ₹19.97 Cr. |
| Share Offered | 17,52,000 Sharea |
| Anchor lock-in period end date for 50% shares [30 Days] | December 14, 2025 |
| Anchor lock-in period end date for remaining shares [90 Days] | February 12, 2026 |
Mahamaya Lifesciences IPO Reservation
| Category | Reservation | Shares Offered |
|---|---|---|
| QIB | 47.39% | 29,28,000 |
| NII | 14.27% | 8,82,000 |
| RII | 33.33% | 20,59,200 |
| Market Maker | 5.01% | 3,09,600 |
| Total | 100.00% | 61,78,800 |
Mahamaya Lifesciences IPO Market Lot
| Application | Lot | Shares | Amount |
| Retail [Min. & Max.] | 2 | 2,400 | ₹2,73,600 |
| S-HNI [Min] | 3 | 3,600 | ₹4,10,400 |
| S-HNI [Max] | 7 | 8,400 | ₹9,57,600 |
| B- HNI [Min] | 8 | 9,600 | ₹10,94,400 |
Key Performance Indicator
| KPI [March 31, 2025] | Value |
| Market Capitalisation | ₹266.82 Cr. |
| P/E Ratio | 15.65x |
| EPS | ₹7.29 |
| ROE | 34.94% |
| ROCE | 23.15% |
| RoNW | 26.19% |
| Dept/Equity | 1.08 |
| EBITDA Margin | 9.22% |
| PAT Margin | 4.84% |
| Net Assets Value | ₹27.82 |
| Price To Book Value | ₹9.40 |
Mahamaya Lifesciences IPO Peer Comparison
| Company | P/E | EPS | RoNW | NAV |
| Nova Agritech Limited | 16.93x | ₹3.05 | 12.47% | ₹23.61 |
| Bhagiradha Chemicals & Industries Limited | 247.63x | ₹1.14 | 2.09% | ₹52.61 |
Mahamaya Lifesciences IPO Dates
| Open Date | November 11, 2025 |
| Close Date | November 13, 2025 |
| Allotment Date | November 14, 2025 |
| Refund Date | November 17, 2025 |
| Share Credit Date | November 17, 2025 |
| Listing Date | November 18, 2025 |
Mahamaya Lifesciences Limited Company Financial Report
| Years | Assets | Income | Expenses | Net Worth | PAT | Borrow |
|---|---|---|---|---|---|---|
| June 2025 | ₹218.87 Cr. | ₹84.04 Cr. | ₹78.35 Cr. | ₹53.50 Cr. | ₹4.10 Cr. | ₹57.72 Cr. |
| March 2025 | ₹188.35 Cr. | ₹267.17 Cr. | ₹249.81 Cr. | ₹49.42 Cr. | ₹12.94 Cr. | ₹58.11 Cr. |
| March 2024 | ₹112.07 Cr. | ₹162.83 Cr. | ₹155.71 Cr. | ₹24.66 Cr. | ₹5.22 Cr. | ₹54.63 Cr. |
| March 2023 | ₹77.88 Cr. | ₹137.40 Cr. | ₹132.30 Cr. | ₹19.44 Cr. | ₹3.75 Cr. | ₹24.37 Cr. |
Company Promoters
- Mr. Krishnamurthy Ganesan
- Mrs. Lalitha Krishnamurthy
- Mr. Prashant Krishnamurthy
| Holding Pre Issue | 77.27% | 1,77,66,200 Sharea |
| Holding Post Issue | 56.35% | 2,34,05,000 Shares |
Mahamaya Lifesciences IPO Lead Managers
- Oneview Corporate Advisors Pvt. Ltd.
Mahamaya Lifesciences IPO Registrar
KFin Technologies Limited
Selenium, Tower B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Rangareddi, Hyderabad, Telangana,
India, 500032
Tel. No.: +91-40-67162222
E-mail: compliance.corp@kfintech.com
Website: https://www.kfintech.com/
About The Company
Founded in 2002, Mahamaya Lifesciences Limited is a trusted name in the agrochemical sector, dedicated to advancing sustainable farming through innovative crop protection and soil health solutions. The company focuses on developing, manufacturing, and exporting premium-quality pesticides and bioproducts that enhance crop productivity and empower farmers to achieve higher yields.
With strong expertise in pesticide formulation, Mahamaya Lifesciences supplies bulk products to leading Indian agrochemical brands as well as global corporations. The company imports scientifically validated molecules, registers them with the Central Insecticides Board, and transforms them into high-value formulations tailored for both domestic and international markets.
Its global presence continues to expand with product registrations and exports to countries such as the Dominican Republic, Egypt, Ethiopia, Jordan, the UAE, and Turkey, ensuring quality-driven agro solutions supported by robust data and regulatory compliance.
The company’s extensive portfolio includes bulk formulation sales (such as Acetamiprid SP, Buprofezin SC, and Paraquat Dichloride SC), technical sales (including Acetamiprid 99% Min and Imidacloprid 95% Min), and branded products like MAYAMRIT GR, MAYAGIBB, and UCHIT EW 370. Its exports feature high-performance formulations like Wiper, Lancha, Tolfen, and Typic.
Mahamaya Lifesciences attributes its success to an experienced leadership team, a commitment to product innovation, strong supplier relationships, and a focus on sustainability that drives every aspect of its operations.
Objects Of The Issue
- Purchase of Equipment for existing Formulation plant
- Funding capital expenditure towards setting up of a new technical manufacturing plant
- Construction of Warehouse Building and Purchase of Machinery
- Funding working capital requirement of our Company
- General Corporate purposes
Company Address
Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
Mahamaya Lifesciences IPO FAQs
What are the open and close dates of the Mahamaya Lifesciences IPO?
The Mahamaya Lifesciences IPO will open on November 11, 2025 and will close on November 13, 2025.
What is the price band for Mahamaya Lifesciences IPO?
The price band for the Mahamaya Lifesciences IPO is fixed at ₹108 to ₹114 per share.
What is the lot size of the Mahamaya Lifesciences IPO?
Investors can apply Mahamaya Lifesciences IPO for a minimum of 2,400 shares per lot and in multiples thereafter.
How can retail investors apply for the Mahamaya Lifesciences IPO?
Retail investors can apply through UPI-based ASBA (Application Supported by Blocked Amount) via their bank or stock broker’s platform.
What is the issue size of the Mahamaya Lifesciences IPO?
The total issue size of Mahamaya Lifesciences Limited IPO is ₹70.44 Cr., comprising both fresh issue and offer for sale (if applicable).
When will the basis of allotment for the Mahamaya Lifesciences IPO be finalized?
The Mahamaya Lifesciences IPO basis of allotment is expected to be finalized on November 14, 2025.
How can I check the allotment status of the Mahamaya Lifesciences IPO?
Investors can check their allotment status on the official registrar’s website once it is announced.
When will the shares of Mahamaya Lifesciences IPO get listed?
The Mahamaya Lifesciences IPO are expected to be listed on the BSE and SME on November 18, 2025.
Is the Mahamaya Lifesciences IPO a good investment?
Investment decisions depend on an individual’s financial goals and risk profile. It is advised to consult with a SEBI-registered financial advisor before making any investment decision.
| Read Also |
|---|
| Mahamaya Lifesciences IPO GMP |
| Mahamaya Lifesciences IPO Subscription |
| Mahamaya Lifesciences IPO Allotment |
Disclaimer: Readers are strongly advised to seek guidance from a qualified financial advisor before making any investment decisions. Relying solely on the content presented here for financial choices is done entirely at the reader’s own risk.
| Thank You… |
|---|